213 related articles for article (PubMed ID: 38302473)
1. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.
Deutzmann A; Sullivan DK; Dhanasekaran R; Li W; Chen X; Tong L; Mahauad-Fernandez WD; Bell J; Mosley A; Koehler AN; Li Y; Felsher DW
Nat Commun; 2024 Feb; 15(1):963. PubMed ID: 38302473
[TBL] [Abstract][Full Text] [Related]
2. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
Wang H; Wang P; Xu M; Song X; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Cell Death Dis; 2021 Feb; 12(2):200. PubMed ID: 33608500
[TBL] [Abstract][Full Text] [Related]
3. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
[TBL] [Abstract][Full Text] [Related]
4. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
5. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
Zhang N; Chen X
Cell Oncol (Dordr); 2020 Feb; 43(1):137-153. PubMed ID: 31691159
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-216b suppresses the cell growth of hepatocellular carcinoma by inhibiting Ubiquitin-specific peptidase 28 expression.
Zhang JF
Kaohsiung J Med Sci; 2020 Jun; 36(6):423-428. PubMed ID: 32053284
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
8. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
9. PTTG1 is involved in TNF-α-related hepatocellular carcinoma via the induction of c-myc.
Lin X; Yang Y; Guo Y; Liu H; Jiang J; Zheng F; Wu B
Cancer Med; 2019 Sep; 8(12):5702-5715. PubMed ID: 31385458
[TBL] [Abstract][Full Text] [Related]
10. Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC.
Ritorto MS; Rhode H; Vogel A; Borlak J
Biol Chem; 2016 Nov; 397(11):1147-1162. PubMed ID: 27232633
[TBL] [Abstract][Full Text] [Related]
11. STK33 promotes hepatocellular carcinoma through binding to c-Myc.
Yang T; Song B; Zhang J; Yang GS; Zhang H; Yu WF; Wu MC; Lu JH; Shen F
Gut; 2016 Jan; 65(1):124-33. PubMed ID: 25398772
[TBL] [Abstract][Full Text] [Related]
12. Hematological and neurological expressed 1 (HN1) activates c-Myc signaling by inhibiting ubiquitin-mediated proteasomal degradation of c-Myc in hepatocellular carcinoma.
Feng J; Liu Y; Fang T; Zhu J; Wang G; Li J
Cell Biol Int; 2023 Mar; 47(3):560-572. PubMed ID: 36403281
[TBL] [Abstract][Full Text] [Related]
13. Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.
Dolezal JM; Wang H; Kulkarni S; Jackson L; Lu J; Ranganathan S; Goetzman ES; Bharathi SS; Beezhold K; Byersdorfer CA; Prochownik EV
J Biol Chem; 2017 Jun; 292(24):10068-10086. PubMed ID: 28432125
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.
Dang H; Takai A; Forgues M; Pomyen Y; Mou H; Xue W; Ray D; Ha KCH; Morris QD; Hughes TR; Wang XW
Cancer Cell; 2017 Jul; 32(1):101-114.e8. PubMed ID: 28697339
[TBL] [Abstract][Full Text] [Related]
15. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
16. GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.
Feng H; Zhu M; Zhang R; Wang Q; Li W; Dong X; Chen Y; Lu Y; Liu K; Lin B; Guo J; Li M
J Cell Mol Med; 2019 Apr; 23(4):2536-2548. PubMed ID: 30672133
[TBL] [Abstract][Full Text] [Related]
17. IFITM3 upregulates c-myc expression to promote hepatocellular carcinoma proliferation via the ERK1/2 signalling pathway.
Min J; Hu J; Luo C; Zhu J; Zhao J; Zhu Z; Wu L; Yuan R
Biosci Trends; 2020 Jan; 13(6):523-529. PubMed ID: 31852866
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
